Oncoinvent is a clinical-stage Norwegian biotech whose lead candidate Radspherin uses short-range radium-224 alpha radiation to treat cancers in body cavities. Radspherin consists of calcium carbonate microparticles containing radium-224 and is produced at Oncoinvent's manufacturing facility in Nydalen, Oslo, while the company has also developed the proprietary antibody OI-1 targeting PTK7.
Radspherin's radium-224 alpha radiation travels under 0.1 mm, concentrating the dose in the cavity and limiting healthy-tissue exposure, while the therapy is receptor independent and works on tumors regardless of antigen expression. Its first clinical target is peritoneal carcinomatosis, cancer that has spread into the peritoneal cavity usually from a tumor in another organ, and Radspherin is in clinical development for ovarian and colorectal cancers that have metastasized to the peritoneum.